Better Health, Brighter Future
CAMBRIDGE, Massachusetts, April 8, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of Food is Health and Building STEM (Science, Technology, Engineering and Math) Foundations and providing larger, multi-year grants to select nonprofits. Combined with previous investments since 2021, Takeda’s total contribution to these initiatives now amounts to $54.1 million.
“By focusing our efforts on Food is Health and Building STEM Foundations, we are evolving our program to address two areas of significant need that will help build up communities and narrow disparities that can prevent people from realizing their full potential," said Julie Kim, president of Takeda’s U.S. Business Unit and U.S. Country Head. "We are excited to continue this important work with our new partners, collectively striving to drive long-term impact within our local communities and more broadly.”
Takeda reviews grant applications for its U.S. CSR program twice a year. The company partners with local and national organizations that align with its philanthropic focus areas, actively listening and valuing their insights and expertise to understand the areas of greatest need within communities. By leveraging this collaborative approach, Takeda provides support to address these critical needs and make a positive impact on people's lives.
Strengthening the Connection Between Food and Health for vulnerable and underserved communities around the country:
Building STEM Foundations to promote educational equity from kindergarten through college:
Takeda recently published Caring for Tomorrow: 2023 U.S. Community Impact Report, an annual report that provides a comprehensive overview of the initiatives and partnerships that are making a difference in the lives of communities across the country. Further details on the company’s U.S. CSR, health equity and diversity, equity and inclusion programs can be found in the report.
Learn more about Takeda’s U.S. CSR Program and its philanthropic strategy here. You can find more details about Takeda’s Global CSR Program here.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
U.S. and International Media
Megan Ostrower [email protected]
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.